- Home
- RSG vs GSK Comparison
RSG vs GSK Comparison
Compare RSG & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSG
- GSK
- Stock Information
- Founded
- RSG 1996
- GSK 1715
- Country
- RSG United States
- GSK United Kingdom
- Employees
- RSG N/A
- GSK N/A
- Industry
- RSG Environmental Services
- GSK Biotechnology: Pharmaceutical Preparations
- Sector
- RSG Utilities
- GSK Health Care
- Exchange
- RSG Nasdaq
- GSK Nasdaq
- Market Cap
- RSG 76.2B
- GSK 71.7B
- IPO Year
- RSG 1998
- GSK N/A
- Fundamental
- Price
- RSG $243.28
- GSK $35.93
- Analyst Decision
- RSG Buy
- GSK Hold
- Analyst Count
- RSG 18
- GSK 4
- Target Price
- RSG $235.18
- GSK $47.00
- AVG Volume (30 Days)
- RSG 1.7M
- GSK 6.0M
- Earning Date
- RSG 04-24-2025
- GSK 04-30-2025
- Dividend Yield
- RSG 0.95%
- GSK 4.32%
- EPS Growth
- RSG 18.65
- GSK N/A
- EPS
- RSG 6.49
- GSK 0.78
- Revenue
- RSG $16,032,000,000.00
- GSK $39,280,393,592.00
- Revenue This Year
- RSG $6.38
- GSK $7.60
- Revenue Next Year
- RSG $5.22
- GSK $5.24
- P/E Ratio
- RSG $37.49
- GSK $22.27
- Revenue Growth
- RSG 7.13
- GSK 3.46
- 52 Week Low
- RSG $180.92
- GSK $31.72
- 52 Week High
- RSG $249.73
- GSK $45.93
- Technical
- Relative Strength Index (RSI)
- RSG 56.89
- GSK 45.54
- Support Level
- RSG $242.30
- GSK $32.38
- Resistance Level
- RSG $247.24
- GSK $36.16
- Average True Range (ATR)
- RSG 7.19
- GSK 1.16
- MACD
- RSG 0.19
- GSK -0.13
- Stochastic Oscillator
- RSG 74.80
- GSK 52.28
About RSG Republic Services Inc.
Republic Services is the second-largest integrated provider of traditional solid waste services in the United States, operating roughly 207 active landfills and 246 transfer stations. The company serves residential, commercial, and industrial end markets. It also runs a sizable recycling operation in North America.
About GSK GSK plc (Each representing two)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.